Venkatesh L Hegde

Dr. Venkatesh L Hegde

Department of Thoracic/Head and Neck Medical Oncology;University of Texas MD Anderson Cancer Center, Houston, TX USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 May 2020 in Vaccines
Verified
Journal Article
Open access
PDF file
GGloria Galvan
Gloria Galvan
Stephanie Dorta-EstremeraStephanie Dorta-Estremera
Stephanie Dorta-Estremera
Venkatesh L HegdeVenkatesh L Hegde
Venkatesh L Hegde
SNSita M. K. Nookala
Sita M. K. Nookala
AYAnanta V. Yanamandra
Ananta V. Yanamandra
JSJagannadha Sastry
Jagannadha Sastry
Human papillomavirus (HPV)-induced cancers continue to affect millions of women around the world, and the five year survival rate under the current standard of care for these cancers is less than 60% in some demographics. Therefore there is still an unmet need to develop an effective therapy that can be easily administered to treat established HPV cervical cancer lesions. We sought to investigate the potential of an intranasal HPV peptide therapeutic vaccine incorporating the combination of α-Galactosylceramide (α-GalCer) and CpG-ODN adjuvants (TVAC) against established HPV genital tumors in a syngeneic C57BL/6J mouse model. We obtained evidence to show that TVAC, delivered by the mucosal intranasal route, induced high frequencies of antigen-specific CD8 T cells concurrent with significant reduction in the immunosuppressive regulatory T cells and myeloid derived suppressor cells in the tumor microenvironment (TME), correlating with sustained elimination of established HPV genital tumors in over 85% of mice. Inclusion of both the adjuvants in the vaccine was necessary for significant increase of antigen-specific CD8 T cells to the tumor and antitumor efficacy because vaccination incorporating either adjuvant alone was inefficient. These results strongly support the utility of the TVAC administered by needle-free intranasal route as a safe and effective strategy for the treatment of established genital HPV tumors.

22 May 2020 in medRxiv
Verified
Preprint
Open access
PDF file
TSTravis T. Sims
Travis T. Sims
MAMolly B. El Alam
Molly B. El Alam
TKTatiana V. Karpinets
Tatiana V. Karpinets
SDStephanie Dorta-Estremera
Stephanie Dorta-Estremera
Venkatesh L HegdeVenkatesh L Hegde
Venkatesh L Hegde
AKAnn Klopp
Ann Klopp
Diversity of the gut microbiome is associated with higher response rates for cancer patients receiving immunotherapy but has not been investigated in patients receiving radiation therapy. Additionally, current studies investigating the gut microbiome and outcomes in cancer patients may not adjusted for established risk factors. Here, we sought to determine if diversity and composition of the gut microbiome was independently associated with survival in cervical cancer patients receiving chemoradiation. Our study demonstrates that the diversity of gut microbiota is associated with a favorable response to chemoradiation. Additionally, compositional variation among patients correlated with short term and long-term survival. Short term survivor fecal samples were significantly enriched in Porphyromonas, Porphyromonadaceae, and Dialister, whereas long term survivor samples were significantly enriched in Escherichia Shigella, Enterobacteriaceae, and Enterobacteriales. Moreover, analysis of immune cells from cervical tumor brush samples by flow cytometry revealed that patients with a high microbiome diversity had increased tumor infiltration of CD4+ lymphocytes as well as activated subsets of CD4 cells expressing ki67+ and CD69+ over the course of radiation therapy. The modulation of gut microbiota before chemoradiation might provide an alternative way to enhance treatment efficacy and improve treatment outcomes in cervical cancer patients.